Brainstorming, page-41

The following are excerpts from the current Biotron patent in November (prior to Covid-19)

Antiviral compounds and methods

TheSARS virus encodes an E protein which is shown for the first time, by thepresent inventors, to act as an ion channel. As similar E proteins are presentin other coronaviruses, the compounds, compositions and methods of the presentinvention would have utility in the inhibition and/or treatment of infectionsby other coronaviruses.

Preferably,the membrane ion channel of which functional activity is down regulated is thatwhich Lentiviruses, and Coronaviruses utilise for mediating viral replicationand include, for example, the HIV membrane ion channel Vpu, the HCV membraneion channel P7, the Coronavirus E protein membrane ion channel, and the SARS Eprotein membrane ion channel.

SARS coronavirus BJ03, SARScoronavirus BJ04, SARS coronavirus CUHK-Su10, SARS coronavirus CUHK-W1, SARScoronavirus Frankfurt 1, SARS coronavirus GZ01, SARS coronavirus HKU-39849, SARScoronavirus Hong Kong ZY-2003, SARS coronavirus Hong Kong/03/2003, SARScoronavirus HSR 1, SARS coronavirus Sin2500, SARS coronavirus Sin2677, SARScoronavirus Sin2679, SARS coronavirus Sin2748, SARS coronavirus Sin2774, SARScoronavirus Taiwan, SARS coronavirus Taiwan JC-2003, SARS coronavirus TaiwanTC1, SARS coronavirus Taiwan TC2, SARS coronavirus Tor2, SARS coronavirus TW1, SARScoronavirus TWC, SARS coronavirus Urbani, SARS coronavirus Vietnam, SARScoronavirus ZJ-HZ01, SARS coronavirus ZJ01 and unclassifiedcoronaviruses

Themethods of the present invention may be particularly useful either in the earlystages of viral infection to prevent the establishment of a viral reservoir inaffected cells or as a prophylactic treatment to be applied immediately priorto or for a period after exposure to a possible source of virus.

Themethod of the present invention may be particularly useful either in the earlystages of viral infection to prevent the establishment of a viral reservoir inaffected cells or as a prophylactic treatment to be applied immediately priorto or for a period after exposure to a possible source of virus.

Referenceherein to “therapeutic” and “prophylactic” is to be considered in theirbroadest contexts. The term “therapeutic” does not necessarily imply that amammal is treated until total recovery. Similarly, “prophylactic” does notnecessarily mean that the subject will not eventually contract a diseasecondition. Accordingly, therapy and prophylaxis include amelioration of thesymptoms of a particular condition or preventing or otherwise reducing the riskof developing a particular condition. The term “prophylaxis” may be consideredas reducing the severity of onset of a particular condition. Therapy may alsoreduce the severity of an existing condition or the frequency of acute attacks.

Someexamples involve the use of the SARS virus. It will be clear from thedescription herein that other lentiviruses, and coronaviruses and othercompounds may be used effectively in the context of the present invention.

Inaccordance with the methods of the present invention, more than one compound orcomposition may be co-administered with one or more other compounds, such asknown anti-viral compounds or molecules.

Thepharmaceutical compositions of the invention may further comprise one or moreknown antiviral compounds or molecules. Preferably, the known antiviral compoundsare selected from the group consisting of Vidarabine, Acyclovir, Ganciclovir,Valganciclovir, Valacyclovir, Cidofovir, Famciclovir, Ribavirin,Amantadine, Rimantadine, Interferon, Oseltamivir,Palivizumab, Rimantadine, Zanamivir, nucleoside-analog reversetranscriptase inhibitors (NRTI) such as Zidovudine, Didanosine,Zalcitabine,Stavudine, Lamivudine and Abacavir, non-nucleoside reversetranscriptase inhibitors (NNRTI) such as Nevirapine, Delavirdine andEfavirenz, protease inhibitors such as Saquinavir, Ritonavir, Indinavir,Nelfinavir, Amprenavir, and other known antiviral compounds andpreparations. Known antiviral compounds or molecules may in some cases actsynergistically with the antiviral compounds of the invention.

The highlighted compounds above that may be co-administered with BIT are compounds that are separately or combined being looked at in the treatment of Covid-19. As such, if BIT is to test its compounds with any/all of the above (and/or any new "antivirdal compounds and preparations") would certainly extend the period for BIT to reach a conclusive result for publication. IMO